Neximmune Competitors

Delisted . USA . 
Stock . Neximmune
NEXIDelisted Stock  USD 2.43  0.22  9.95%   
Neximmune competes with ZyVersa Therapeutics, Palisade Bio, Unicycive Therapeutics, Immix Biopharma, and Transcode Therapeutics; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing Neximmune competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Neximmune to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Neximmune competition on your existing holdings.
  
Specify up to 10 symbols:
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Neximmune's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
2.432.432.43
Details
Intrinsic
Valuation
LowRealHigh
2.352.352.67
Details
Naive
Forecast
LowNextHigh
2.542.542.54
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
2.162.823.48
Details

Neximmune Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Neximmune and its competitors represents the degree of relationship between the price movements of corresponding pink sheets. A correlation of about +1.0 implies that the price of Neximmune and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Neximmune does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
ONCR
+ 0.87
PALI
ONCR
+ 0.84
ZVSA
PALI
+ 0.76
ZVSA
LABP
+ 0.73
UNCY
EFTR
+ 0.58
ZVSA
EFTR
+ 0.49
IMMX
  
High negative correlations   
ONCR
- 0.81
UNCY
RNAZ
- 0.77
IMMX
ONCR
- 0.75
LABP
LABP
- 0.74
ZVSA
UNCY
- 0.74
ZVSA
LABP
- 0.72
PALI

Risk-Adjusted Indicators

There is a big difference between Neximmune Pink Sheet performing well and Neximmune Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Neximmune's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
ZVSA  4.40 (1.23) 0.00  0.76  0.00 
 0.00 
 7.57 
(10.36)
 78.93 
PALI  3.53 (0.52) 0.00 (1.96) 0.00 
 0.00 
 5.97 
(8.55)
 24.25 
UNCY  4.00  0.46  0.09  0.37  4.24 
(5.20)
 9.76 
(7.41)
 29.22 
APGN  5.12  0.02  0.00  0.13  5.50 
(7.45)
 7.89 
(11.11)
 58.79 
IMMX  3.80 (0.45) 0.00 (0.26) 0.00 
 0.00 
 7.06 
(8.22)
 32.68 
RNAZ  7.83  1.22  0.13 (0.64) 6.58 
(11.84)
 22.00 
(11.43)
 68.80 
LABP  3.55  0.56  0.10 (3.18) 3.81 
(3.77)
 8.58 
(7.05)
 19.47 
ONCR  8.13 (1.86) 0.00  0.78  0.00 
 0.00 
 10.00 
(21.20)
 120.67 
XBIO  3.88  0.07  0.00  0.43  4.50 
(4.52)
 7.65 
(7.27)
 26.99 
EFTR  7.57 (4.70) 0.00 (3.44) 0.00 
 0.00 
 8.70 
(27.78)
 88.91 
All Fundamental Data

Neximmune Competitive Analysis

The better you understand Neximmune competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Neximmune's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Neximmune's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
NEXI ZVSA PALI UNCY APGN IMMX RNAZ LABP ONCR XBIO
 9.95 
 2.43 
Neximmune
 0.87 
 1.14 
ZyVersa
 0.41 
 2.44 
Palisade
 3.92 
 0.53 
Unicycive
 2.27 
 0.43 
Apexigen
 7.69 
 1.68 
Immix
 11.76 
 0.38 
Transcode
 3.60 
 4.02 
Landos
 14.71 
 0.04 
Oncorus
 0.50 
 4.01 
Xenetic
Market Volatility
(90 Days Market Risk)
Very steady
Abnormally volatile
Very risky
Out of control
Very steady
Dangerous
Out of control
Very steady
Very steady
Risky
Market Performance
(90 Days Performance)
Very Weak
Very Weak
Very Weak
OK
Very Weak
Very Weak
OK
Very Weak
Very Weak
Weak
Odds of Financial Distress
(Probability Of Bankruptcy)
Dangerous
Average
Very High
Low
Dangerous
Average
High
Dangerous
Dangerous
Very High
Current Valuation
(Equity Enterprise Value)
Fairly Valued
Over Valued
Fairly Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Strong Buy
Strong Buy
Strong Buy
Not Available
Buy
Buy
Not Available
Not Available
Hold
Trade Advice
(90 Days Macroaxis Advice)
Not Rated
Strong Sell
Strong Sell
Hold
Not Rated
Strong Sell
Strong Sell
Not Rated
Not Rated
Strong Sell
Current Ratio
6.54
N/A
2.59
4.43
1.24
19.53
8.06
8.91
6.42
12.02
Net Asset
8.59 M
22.11 M
14.05 M
14.19 M
22.86 M
19.93 M
5.17 M
38.04 M
145.59 M
10.61 M
Profit Margin
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
-1.86
EBITDA
(28.17 M)
(107.74 M)
(12.28 M)
(30.18 M)
(32.58 M)
(16.14 M)
(17.97 M)
(22.73 M)
(75.42 M)
(4.52 M)
Current Valuation
(491.95 K)
(456.64 K)
(3.95 M)
23.24 M
205.33 K
27.61 M
4.84 M
42.67 M
25.71 M
(684.62 K)
Price To Book
1.38
0.38
0.56
1.97
2.32
2.63
3.97
2.11
0.13
0.87
Operating Margin
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
-1.84
Retained Earnings
(222.59 M)
(103.22 M)
(121.51 M)
(64.54 M)
(176.79 M)
(53.41 M)
(46.42 M)
(155.36 M)
(272.01 M)
(193.23 M)
Current Asset
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
1.21 M
Beta
1.94
0.64
1.33
2.29
3.62
0.1
0.65
0.14
2.85
2.26
Number Of Employees
6
7
9
14
11
14
10
19
64
4
Shares Outstanding
1.37 M
2.34 M
1.33 M
103.8 M
24.86 M
27.51 M
17.27 M
3.13 M
26.09 M
1.54 M
Cash Flow From Operations
(31.43 M)
(8.72 M)
(11.13 M)
(18.28 M)
(30.69 M)
(11.37 M)
(18.07 M)
(20.48 M)
(61.69 M)
(4.11 M)
Total Debt
68.81 K
8.66 K
369 K
811 K
106 K
3.72 M
450.57 K
27 K
70.65 M
809.59 K
Return On Equity
-1.96
-1.52
-1.1
-1.22
-15.98
-1.04
-10.49
-0.71
-1.25
-0.49
Z Score
N/A
N/A
N/A
N/A
38.91
N/A
N/A
N/A
-4.07
N/A
Return On Asset
-0.7
-0.25
-0.59
-0.53
-0.89
-0.57
-2.08
-0.39
-0.32
-0.29
Number Of Shares Shorted
15.99 K
45.48 K
43.11 K
1.05 M
64.45 K
434.94 K
743.58 K
1.43 K
447.72 K
14.83 K
Book Value Per Share
2.0
27.33
18.3
-0.11
-0.093
0.82
2.62
7.43
1.19
6.36
Current Liabilities
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
4.97 M
Total Asset
8.59 M
22.11 M
14.05 M
14.19 M
22.86 M
19.93 M
5.17 M
38.04 M
145.59 M
10.61 M
Debt To Equity
0.023
N/A
0.23
0.023
0.054
0.002
N/A
N/A
0.72
N/A
Short Ratio
2.26
0.19
0.29
0.74
1.72
2.94
0.5
0.08
0.74
0.77
Target Price
2.0
20.0
30.33
5.5
0.64
7.0
3.0
12.71
5.0
40.0
Shares Owned By Institutions
11.17
4.47
3.57
38.2
13.54
17.64
1.99
52.04
55.29
2.09
Market Capitalization
3.25 M
2.67 M
3.73 M
54.78 M
9.57 M
46.21 M
6.56 M
71.68 M
3.15 M
6.19 M
Price To Earning
N/A
N/A
0.16
N/A
N/A
N/A
N/A
N/A
N/A
-1.81
Price To Earnings To Growth
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Price To Sales
N/A
N/A
14.03
62.82
N/A
N/A
N/A
2.37
N/A
2.46
Net Income
(32.34 M)
(98.3 M)
(12.3 M)
(30.54 M)
(32.07 M)
(15.6 M)
(18.55 M)
(21.93 M)
(77.42 M)
(4.13 M)
Earnings Per Share
-24.11
491.97
-13.26
-0.46
-1.71
-0.84
168.84
-4.0
-5.49
-2.66
Shares Owned By Insiders
17.0
0.61
1.88
6.73
8.81
40.09
0.009
9.88
12.69
19.05
Revenue
N/A
N/A
250 K
675 K
N/A
N/A
N/A
N/A
N/A
2.54 M
Working Capital
316.73 K
(6.84 M)
10.74 M
(4.13 M)
4.73 M
16.07 M
964.85 K
31.79 M
27.41 M
8.78 M
Cash And Equivalents
53.13 M
N/A
5 M
10.57 M
21.62 M
18.4 M
13.45 M
55.75 M
100.24 M
14.93 M
Cash Per Share
2.2
N/A
0.23
0.7
1.01
1.32
1.04
1.38
3.86
1.04
Gross Profit
N/A
N/A
N/A
N/A
N/A
N/A
N/A
18 M
N/A
1.16 M
Day Typical Price
2.39
1.15
2.56
0.52
0.44
1.74
0.37
4.08
0.0472
3.95
Accumulation Distribution
0.17
0.0508
0.19
0.0741
0.11
0.13
0.15
0.0794
0.37
0.0522
Market Facilitation Index
0.44
0.06
0.54
0.04
0.05
0.24
0.06
0.34
0.022
0.21
Daily Balance Of Power
0.5
(0.17)
0.0185
0.5
(0.20)
(0.58)
0.6667
(0.44)
(0.34)
0.0952
Period Momentum Indicator
0.22
(0.01)
0.01
0.02
(0.01)
(0.14)
0.04
(0.15)
(0.01)
0.02
Rate Of Daily Change
1.1
0.99
1.0
1.04
0.98
0.92
1.12
0.96
0.85
1.01
Day Median Price
2.37
1.15
2.62
0.52
0.44
1.77
0.36
4.11
0.049
3.92
Price Action Indicator
0.17
(0.01)
(0.18)
0.02
(0.02)
(0.16)
0.04
(0.17)
(0.01)
0.1
Coefficient Of Variation
(3,356)
(603.75)
(1,011)
830.61
8455.47
(1,714)
1115.0
842.41
(655.56)
5140.53
Mean Deviation
4.85
4.4
3.53
4.0
5.12
3.8
7.83
3.55
8.13
3.88
Jensen Alpha
(0.36)
(1.23)
(0.52)
0.462
0.0246
(0.45)
1.22
0.5551
(1.86)
0.0677
Total Risk Alpha
(1.66)
(2.53)
(1.13)
(0.06)
(1.05)
(1.04)
(0.50)
(0.06)
(3.95)
(0.57)
Sortino Ratio
N/A
N/A
N/A
0.0921
(0.0009)
N/A
0.1251
0.0974
N/A
(0)
Downside Variance
N/A
N/A
N/A
33.52
43.89
N/A
58.75
20.3
N/A
21.54
Standard Deviation
10.32
8.5
4.88
5.34
8.75
5.47
11.92
4.62
13.92
5.05
Kurtosis
34.29
13.44
3.24
1.46
12.89
4.25
6.73
0.0588
11.31
0.8706
Potential Upside
5.9
7.57
5.97
9.76
7.89
7.06
22.0
8.58
10.0
7.65
Treynor Ratio
(0.72)
0.7572
(1.96)
0.3689
0.1349
(0.26)
(0.64)
(3.18)
0.7837
0.4271
Maximum Drawdown
94.3
78.93
24.25
29.22
58.79
32.68
68.8
19.47
120.67
26.99
Variance
106.45
72.3
23.86
28.49
76.64
29.96
142.0
21.33
193.82
25.48
Market Risk Adjusted Performance
(0.71)
0.7672
(1.95)
0.3789
0.1449
(0.25)
(0.63)
(3.17)
0.7937
0.4371
Risk Adjusted Performance
(0.01)
(0.12)
(0.07)
0.1004
0.0181
(0.04)
0.0778
0.0989
(0.11)
0.0233
Skewness
4.71
0.2999
0.5299
0.5903
2.85
1.34
2.22
0.2863
0.7357
0.3501
Semi Deviation
N/A
N/A
N/A
4.24
5.5
N/A
6.58
3.81
N/A
4.5
Information Ratio
(0.04)
(0.18)
(0.12)
0.0999
(0.0007)
(0.08)
0.0805
0.095
(0.16)
(0)
Value At Risk
(9.00)
(10.36)
(8.55)
(7.41)
(11.11)
(8.22)
(11.43)
(7.05)
(21.20)
(7.27)
Expected Short fall
N/A
N/A
N/A
(5.20)
(7.45)
N/A
(11.84)
(3.77)
N/A
(4.52)
Downside Deviation
N/A
N/A
N/A
5.79
6.62
N/A
7.66
4.51
N/A
4.64
Semi Variance
N/A
N/A
N/A
17.96
30.2
N/A
43.33
14.54
N/A
20.24

Neximmune Competition Performance Charts

Five steps to successful analysis of Neximmune Competition

Neximmune's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Neximmune in relation to its competition. Neximmune's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Neximmune in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Neximmune's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Neximmune, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Neximmune position

In addition to having Neximmune in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Driverless Cars Thematic Idea Now

Driverless Cars
Driverless Cars Theme
It encompasses large technology companies, automotive makers, security firms, and thematic ETFs across multiple industries. These entities are directly or indirectly involved in shaping the development and marketing of self-driving vehicles. The Driverless Cars theme has 36 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Driverless Cars Theme or any other thematic opportunities.
View All  Next Launch
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.
You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.

Other Consideration for investing in Neximmune Pink Sheet

If you are still planning to invest in Neximmune check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Neximmune's history and understand the potential risks before investing.
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY